Fax: (713) 794-4902
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid
Article first published online: 1 SEP 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 9, pages 2507–2515, 1 May 2012
How to Cite
Sharma, M., Khan, H., Thall, P. F., Orlowski, R. Z., Bassett, R. L., Shah, N., Bashir, Q., Parmar, S., Wang, M., Shah, J. J., Hosing, C. M., Popat, U. R., Giralt, S. A., Champlin, R. E. and Qazilbash, M. H. (2012), A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer, 118: 2507–2515. doi: 10.1002/cncr.26517
- Issue published online: 20 APR 2012
- Article first published online: 1 SEP 2011
- Manuscript Accepted: 28 JUL 2011
- Manuscript Revised: 27 JUL 2011
- Manuscript Received: 8 JUN 2011
- autologous transplantation;
- arsenic trioxide;
Bortezomib is active for newly diagnosed and relapsed multiple myeloma, and it has synergistic activity with melphalan. The authors of this report conducted a randomized trial to determine the safety and efficacy of adding bortezomib to a preparative regimen of arsenic trioxide (ATO), ascorbic acid (AA), and melphalan.
Among 60 patients who enrolled between October 2006 and September 2007, 58 patients underwent autologous transplantation with a preparative regimen of melphalan 200 mg/m2 intravenously, AA 1000 mg daily intravenously for 7 days, and ATO 0.25 mg/kg intravenously for 7 days. Patients were randomized to receive no bortezomib (Group 1), bortezomib 1 mg/m2 × 3 doses (Group 2), and bortezomib 1.5 mg/m2 × 3 doses (Group 3). Primary endpoints were complete response (CR), grade IV toxicity, and 90-day treatment-related mortality (TRM). Secondary endpoints were progression-free survival (PFS) and overall survival (OS).
The median follow-up of all surviving patients was 36 months (range, 20-43 months). The CR rates in Groups 1, 2, and 3 were 20%, 10%, and 10%, respectively. Grade 3 and 4 nonhematologic toxicities and TRM were comparable. The median OS was not reached in the groups, whereas the median PFS in Groups 1, 2, and 3 was 17.8 months, 17.4 months, and 20.7 months, respectively. PFS and OS were significantly shorter in patients who had high-risk cytogenetics (P = .016 and P = .0001, respectively) and relapsed disease (P = .0001 and P = .0001, respectively) regardless of the treatment group.
Adding bortezomib to a preparative regimen of ATO, AA, and high-dose melphalan was safe and well tolerated in patients with multiple myeloma. There was no significant improvement in the CR rate, PFS, or OS in the bortezomib groups. Cancer 2012;. © 2011 American Cancer Society.